Targeted delivery across the blood–brain barrier

Bibliography

• EHRLICH P: In: Das Sauerstojf-Bedurfiiis des Organismus: eine farbenanalytische Studie. Hirschwald, Berlin, Germany (1885)
   Google Scholar
• GOLDMAN EE: Vitalfarbung am Zentralnervensystem. Abh. Preuss. Akad. Wiss. Phys. Math. (1913) K1(1):1–60
   Google Scholar
• PARDRIDGE WM: Drug and gene delivery to the brain: the vascular route. Neuron (2002) 36(4):555–558
   PubMed Web of Science ®Google Scholar
• BEGLEY DJ: Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther. (2004) 104(1):29–45
   PubMed Web of Science ®Google Scholar
• PARDRIDGE WM: Blood-brain barrier biology and methodology. J. Neurovirol (1999) 5(0:556–569
   PubMedGoogle Scholar
• WM Pardridge (Ed.), University Press, Cambridge, UK (2001):1–12. xcellent book on drug targeting and delivery strategies to the brain
   Google Scholar
• RUBIN LL, STADDON JM: The cell biology of the blood-brain barrier. Ann. Rev. Neurosci. (1999) 22: 11–28
   Google Scholar
• WM Pardridge (Ed.), Raven Press, New York, NY, USA (1991):52–98
   Google Scholar
• BRIGHTMAN MW, REESE TS: Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell Biol. (1969) 40(3):648–677
   PubMed Web of Science ®Google Scholar
• REESE TS, KARNOVSKY MJ: Fine structural localization of a blood—brain barrier to exogenous peroxidase. J. Cell Biol. (1967) 34(1):207–217
   PubMed Web of Science ®Google Scholar
• DEBAULT LE, CANCILLA PA: y-Glutamyl transpeptidase in isolated brain endothelial cells: induction by glial cells in vitro. Science (1980) 207(4431):653–655
   PubMed Web of Science ®Google Scholar
• HENDRY SH, JONES EG, BEINFELD MC: Cholecystokinin-immunoreactive neurons in rat and monkey cerebral cortex make symmetric synapses and have intimate associations with blood vessels. Proc. Natl. Acad. Sci. USA (1983) 80(8):2400–2404
   PubMed Web of Science ®Google Scholar
• BALABANOV R, DORE-DUFFY P: Role of the CNS microvascular pericyte in the blood-brain barrier. J. Neurosci. Res. (1998) 53(6):637–644
   PubMed Web of Science ®Google Scholar
• DE BOER AG, VAN DER SANDT IC, GAILLARD PJ: The role of drug transporters at the blood-brain barrier. Ann. Rev. PharmacoL lbxicoL (2003) 43:629–656
   PubMed Web of Science ®Google Scholar
• Pharmacology of the Blood-Brain Barrier. MW Bradbury (Ed.), Springer-Verlag, Berlin, Germany (1992):371–396
   Google Scholar
• BRADBURY MW: The Concept of a Blood-Brain Barrier. John Wiley 8c Sons Ltd., Chichester, UK (1979)
   Google Scholar
• ••This book outlines the concepts of theblood-brain barrier
   Google Scholar
• PARDRIDGE WM: Transport of small molecules through the blood-brain barrier: biology and methodology. Adv. DrugDeliv. Rev (1995) 15:5–36
   PubMed Web of Science ®Google Scholar
• STEIN WD: In: The movement of molecules across cell membranes. Academic Press, New York, NY, USA (1967)
   Google Scholar
• ABRAHAM MH, CHADHA HS, MITCHELL RC: Hydrogen bonding. 33. Factors that influence the distribution of solutes between blood and brain. J. Pharm. Sci. (1994) 83(9):1257–1268
   PubMed Web of Science ®Google Scholar
• LIPINSKI CA, LOMBARDO F, DOMINY BW, FEENEY PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. (2001) 46(1-3):3–26
   PubMed Web of Science ®Google Scholar
• BICKEL U, YOSHIKAWA T, PARDRIDGE WM: Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev. (2001) 46(1-3):247–279
   PubMed Web of Science ®Google Scholar
• VORBRODT AW: Ultracytochemical characterization of anionic sites in the wall of brain capillaries. J. NeurocytoL (1989) 18(3):359–368
   PubMedGoogle Scholar
• DEGUCHI Y, NAITO T, YUGE T et al.: Blood-brain barrier transport of125I-labeled basic fibroblast growth factor. Pharm. Res. (2000) 17(1):63–69
   PubMed Web of Science ®Google Scholar
• DEGUCHI Y, MIYAKAWA Y, SAKURADA S et al.: Blood-brain barrier transport of a novel micro 1-specific opioid peptide, H-Tyr-D-Arg-Phe-B-Ala-OH (TAPA). j Neurochem. (2003) 84(5):1154–1161
   PubMed Web of Science ®Google Scholar
• LOCKMAN PR, KOZIARA JM, MUMPER RJ, ALLEN DD: Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J. Drug Target. (2004) 12(9-10):635–641
   PubMed Web of Science ®Google Scholar
• ABBOTT NJ, ROMERO IA: Transporting therapeutics across the blood-brain barrier. Mot Med. Today (1996) 2(3):106–113
   PubMedGoogle Scholar
• TAMAI I, TSUJI A: Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci. (2000) 89(11):1371–1388
   PubMed Web of Science ®Google Scholar
• TSUJI A, TAMAI II: Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev. (1999) 36(2–3):277–290
   Google Scholar
• DUFFY KR, PARDRIDGE WM: Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res. (1987) 420(1):32–38
   PubMed Web of Science ®Google Scholar
• MOOS T, MORGAN EH: Transferrin and transferrin receptor function in brain barrier systems. Cell. Mol. NeurobioL (2000) 20(1):77–95
   PubMed Web of Science ®Google Scholar
• ••Excellent overview of the biology of the transferrin system at the blood-brain barrier
   Google Scholar
• PARDRIDGE WM, EISENBERG J, YANG J: Human blood-brain barrier transferrin receptor. Metabolism (1987) 36(9):892–895
   PubMed Web of Science ®Google Scholar
• DEHOUCK B, FENART L, DEHOUCK MP et al.: A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J. Cell Biol. (1997) 138(4):877–889
   PubMed Web of Science ®Google Scholar
• BJORBAEK C, ELMQUIST JK, MICHL P et al.: Expression of leptin receptor isoforms in rat brain microvessels. Endocrinology (1998) 139(8):3485–3491
   Google Scholar
• DUFFY KR, PARDRIDGE WM, ROSENFELD RG: Human blood-brain barrier insulin-like growth factor receptor. Metabolism (1988) 37(2):136–140
   PubMed Web of Science ®Google Scholar
• MERCIER C, MASSEGUIN C, ROUX F, GABRION J, SCHERRMANN JM: Expression of P-glycoprotein (ABCB1) and Mrpl (ABCC1) in adult rat brain: focus on astrocytes. Brain Res. (2004) 1021(1):32–40
   PubMed Web of Science ®Google Scholar
• Sharma HS , Wesman J (Eds), Elsevier Academic Press, San Diego, CA, USA (2004):63–72
   Google Scholar
• ZHANG Y, HAN H, ELMQUIST WF, MILLER DW: Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res. (2000) 876(1-2):148–153
   PubMed Web of Science ®Google Scholar
• LEE G, DALLAS S, HONG M, BENDAYAN R: Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. PharmacoL Rev. (2001) 53 (4): 569–596
   PubMed Web of Science ®Google Scholar
• PARDRIDGE WM: Blood-brain barrier drug targeting: the future of brain drug development. Mol. Interv. (2003) 3(2):90–105, 151
   PubMedGoogle Scholar
• AIRD RB: A study of intrathecal, cerebrospinal fluid-to-brain exchange. Exp. NeuroL (1984) 86(2):342–358
   PubMed Web of Science ®Google Scholar
• MILLER G: Drug targeting. Breaking down barriers. Science (2002) 297(5584):1116–1118
   PubMed Web of Science ®Google Scholar
• •Nice overview of the blood-brain barrier problem for the delivery of drugs to the brain
   Google Scholar
• CONNER SD, SCHMID SL: Regulated portals of entry into the cell. Nature (2003) 422(6927):37–44
   PubMed Web of Science ®Google Scholar
• GUMBLETON M, ABULROB AG, CAMPBELL L: Caveolae: an alternative membrane transport compartment. Pharm. Res. (2000) 17(9):1035–1048
   PubMed Web of Science ®Google Scholar
• Zakin D , Boyer TD (Eds), Saunders, Philadelpia, PA, USA (1996):526–554
   Google Scholar
• PONKA P, LOK CN: The transferrin receptor: role in health and disease. Int J. Biochem. Cell Biol. (1999) 31(10):1111–1137
   PubMed Web of Science ®Google Scholar
• ZHANG Y, PARDRIDGE WM: Rapid transferrin efflux from brain to blood across the blood-brain barrier. J. Neurochem. (2001) 76(5):1597–1600
   PubMed Web of Science ®Google Scholar
• PARDRIDGE WM, BUCIAK JL, FRIDEN PM: Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J. PharmacoL Exp. Ther. (1991) 259(1):66–70
   PubMed Web of Science ®Google Scholar
• MOOS T, MORGAN EH: The significance of the mutated divalent metal transporter (DMT1) on iron transport into the Belgrade rat brain. J. Neurochem. (2004) 88(1):233–245
   PubMed Web of Science ®Google Scholar
• DEANE R, ZHENG W, ZLOKOVIC BV: Brain capillary endothelium and choroid plexus epithelium regulate transport of transferrin-bound and free iron into the rat brain. J. Neurochem. (2004) 88(4):813–820
   PubMed Web of Science ®Google Scholar
• PARDRIDGE WM, BOADO RJ, KANG YS: Vector-mediated delivery of a polyamide (peptide') nucleic acid analogue through the blood-brain barrier in vivo. Proc. Natl. Acad. Sci. USA (1995) 92(12):5592–5596
   PubMed Web of Science ®Google Scholar
• SHIN BOADO RJ, PARDRIDGE WM: Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm. Res. (2001) 18(8):1091–1095
   PubMed Web of Science ®Google Scholar
• ZHANG YF, BOADO RJ, PARDRIDGE WM: Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes. Pharm. Res. (2003) 20(11):1779–1785
   PubMed Web of Science ®Google Scholar
• BROAD WELL RD, BAKER-CAIRNS BJ,FRIDEN PM, OLIVER C, VILLEGAS JC: Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor. Exp. Neurol. (1996) 142(1):47–65
   PubMed Web of Science ®Google Scholar
• MOOS T, MORGAN EH: Restricted transport of anti-transferrin receptor antibody (0X26) through the blood-brain barrier in the rat. J. Neurochem. (2001) 79(1):119–129
   PubMed Web of Science ®Google Scholar
• VAN GELDER W, HUIJSKES-HEINS MI, CLETON-SOETEMAN MI, VAN DIJK JP, VAN EIJK HG: Iron uptake in blood-brain barrier endothelial cells cultured in iron-depleted and iron-enriched media. J. Neurochem. (1998) 71(3):1134–1140
   Google Scholar
• VISSER CC, VOORWINDEN LH, CROMMELIN DJ, DANHOF M, DE BOER AG: Characterization and modulation of the transferrin receptor on brain capillary endothelial cells. Pharm. Res. (2004) 21(5):761–769
   PubMed Web of Science ®Google Scholar
• PARDRIDGE WM: Drug and gene targeting to the brain via blood-brain barrier receptor-mediated transport systems. Int. Congres Series 1277(2005) (In press)
   Google Scholar
• •Most recent overview of the work of Pardridge on the targeted delivery of drugs across the blood-brain barrier
   Google Scholar
• The Future of Brain Drug Development. WM Pardridge (Ed.), University Press, Cambridge, UK (2001):126–154
   Google Scholar
• XU L, TANG WH, HUANG CC et al.: Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mo/. Med. (2001) 7(10):723–734
   Google Scholar
• LEE JH, ENGLER JA, COLLAWN JF, MOORE BA: Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur. j Biochem. (2001) 268(7):2004–2012
   PubMedGoogle Scholar
• BOTTARO DP, BONNER-WEIR S, KING GL: Insulin receptor recycling in vascular endothelial cells. Regulation by insulin and phorbol ester. J. Biol. Chem. (1989) 264(10):5916–5923
   PubMed Web of Science ®Google Scholar
• WU D, YANG J, PARDRIDGE WM: Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J. Clin. Invest. (1997) 100(7):1804–1812
   PubMed Web of Science ®Google Scholar
• COLOMA MJ, LEE HJ, KURIHARA A et al.: Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm. Res. (2000) 17(3):266–274
   PubMed Web of Science ®Google Scholar
• HERZ J, STRICKLAND DK: LRP: a multifunctional scavenger and signaling receptor. J. Clin. Invest. (2001) 108(6):779–784
   PubMed Web of Science ®Google Scholar
• HERZ J: LRP: a bright beacon at the blood-brain barrier. J. Clin. Invest. (2003) 112(10):1483–1485
   PubMed Web of Science ®Google Scholar
• BOUCHER P, GOTTHARDT M, LI WP, ANDERSON RG, HERZ J: LRP: role in vascular wall integrity and protection from atherosclerosis. Science (2003) 300(5617):329–332
   PubMed Web of Science ®Google Scholar
• YEPES M, SANDKVIST M, MOORE EG et al.: Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. Clin. Invest. (2003) 112(10):1533–1540
   Google Scholar
• DEMEULE M, POIRIER J, JODOIN J et al.: High transcytosis of melanotransferrin (P97) across the blood-brain barrier. J. Neurochem. (2002) 83(4):924–933. The first report on the use of melanotransferrin as potential carrier protein for drugs across the blood-brain barrier
   PubMed Web of Science ®Google Scholar
• DEANE R, WU Z, ZLOKOVIC BV: RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid 0-peptide clearance through transport across the blood-brain barrier. Stroke (2004) 35(11 Suppl. 1):2628–2631
   PubMedGoogle Scholar
• CHUN JT, WANG L, PASINETTI GM, FINCH CE, ZLOKOVIC BV: Glycoprotein 330/megalin (LRP-2) has low prevalence as mRNA and protein in brain microvessels and choroid plexus. Exp. NeuroL (1999) 157(1):194–201
   PubMed Web of Science ®Google Scholar
• RICHARDSON DR, MORGAN EH: The transferrin homologue, melanotransferrin (p97), is rapidly catabolized by the liver of the rat and does not effectively donate iron to the brain. Biochim. Biophys. Acta (2004) 1690(2):124–133
   PubMed Web of Science ®Google Scholar
• GABATHULER R, ARTHUR G, KENNARD M et al.: Development of a potential vector (NeuroTrans) to deliver drugs across the blood-brain barrier. Int. Congres Series 1277(2005) (In press)
   Google Scholar
• PAN W, KASTIN AJ, ZANKEL TC et al.: Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J. Cell Sci. (2004) 117(Pt 21):5071–5078
   PubMed Web of Science ®Google Scholar
• SEDRAKYAN A, TREASURE T, ELEFTERIADES JA: Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. Thorac Cardiovasc. Surg. (2004) 128(3):442–448
   Web of Science ®Google Scholar
• JEFFERIES WA, FOOD MR, GABATHULER R et al.: Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin. Brain Res. (1996) 712(1):122–126
   PubMed Web of Science ®Google Scholar
• DEANE R, DU YAN S, SUBMAMARYAN RK, et al.: RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. (2003) 9(7):907–913
   PubMed Web of Science ®Google Scholar
• ZLOKOVIC BV: Cerebrovascular transport of Alzheimer's amyloid beta and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain barrier. Life Sc1 (1996) 59(18):1483–1497
   Google Scholar
• ZLOKOVIC BV MARTEL CL, MATSUBARA E et al.: Glycoprotein 330/ megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer's disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc. Nail. Acad. Sci. USA (1996) 93(9):4229–4234
   PubMed Web of Science ®Google Scholar
• DEMEULE M, BERTRAND Y, MICHAUD-LEVESQUE J et al.: Regulation of plasminogen activation: a role for melanotransferrin (p97) in cell migration. Blood (2003) 102(5):1723–1731
   PubMed Web of Science ®Google Scholar
• GAILLARD PJ, BRINK A. DE BOER AG: Diphtheria toxin receptor-targeted brain drug delivery. Int. Congres Series 1277 (2005) (In press)
   Google Scholar
• ••The first report on the use of CRA/1197 asa carrier protein for drugs across the blood-brain barrier
   Google Scholar
• ANDERSON P: Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM197. Infect. Immun. (1983) 39(1):233–238
   PubMed Web of Science ®Google Scholar
• BUZZI S, RUBBOLI D, BUZZI G et al.:CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. Cancer ImmunoL Immunother. (2004) 53(11):1041–1048
   PubMed Web of Science ®Google Scholar
• •Study on the systemic administration of CRA/1197 in humans
   Google Scholar
• RAAB G, KLAGSBRUN M: Heparin-binding EGF-like growth factor. Biochim. Biophys. Acta (1997) 1333(3):F179–199
   PubMed Web of Science ®Google Scholar
• ••Excellent overview on the biology ofHB-EGF or diphtheria toxin receptor
   Google Scholar
• MISHIMA K, HIGASHIYAMA S, NAGASHIMA Y et al.: Regional distribution of heparin-binding epidermal growth factor-like growth factor mRNA and protein in adult rat forebrain. Neurosci. Lett. (1996) 213(3):153–156
   PubMed Web of Science ®Google Scholar
• MISHIMA K, HIGASHIYAMA S, ASAI A et al.: Heparin-binding epidermal growth factor-like growth factor stimulates mitogenic signaling and is highly expressed in human malignant gliomas. Acta NeuropathoL (1998) 96(4):322–328
   PubMed Web of Science ®Google Scholar
• TANAKA N, SASAHARA M, OHNO M et al.: Heparin-binding epidermal growth factor-like growth factor mRNA expression in neonatal rat brain with hypoxic/ischemic injury. Brain Res. (1999) 827(1–2)
   Google Scholar
• GAILLARD PJ, VOORWINDEN LH, NIELSEN JL et al.: Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur. Pharm. Sci. (2001) 12(3):215–222
   PubMed Web of Science ®Google Scholar
• MITAMURA T, HIGASHIYAMA S, TANIGUCHI N, KLAGSBRUN M, MEKADA E: Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J. Biol. Chem. (1995) 270(3):1015–1019
   PubMed Web of Science ®Google Scholar
• CHA JH, CHANG MY, RICHARDSON JA, EIDELS L: Transgenic mice expressing the diphtheria toxin receptor are sensitive to the toxin. MoL MicrobioL (2003) 49(1):235–240
   PubMed Web of Science ®Google Scholar
• BENDELL JC, DOMCHEK SM, BURSTEIN HJ et al.: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer (2003) 97(12):2972–2977
   PubMed Web of Science ®Google Scholar